Theodore Johnson
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Protein Kinase Regulation and GTPase Signaling, Monoclonal and Polyclonal Antibodies Research, Computational Drug Discovery Methods, Advanced Proteomics Techniques and Applications
Most-Cited Works
- → Protein tyrosine phosphatase 1B inhibitors for diabetes(2002)648 cited
- → A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors(2014)359 cited
- → First total synthesis of Lycopodium alkaloids of the magellanane group. Enantioselective total syntheses of (-)-magellanine and (+)-magellaninone(1993)129 cited
- → Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics(2003)115 cited
- → Evaluation of a Published in Silico Model and Construction of a Novel Bayesian Model for Predicting Phospholipidosis Inducing Potential(2007)97 cited
- → Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR(2017)89 cited
- → Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design(2012)79 cited
- → Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. Part 7: Structure–Activity Studies of Bicyclic 2-Pyridone-Containing Peptidomimetics(2002)78 cited
- → A Strategy for Risk Management of Drug-Induced Phospholipidosis(2009)70 cited
- → Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library(1998)68 cited